177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma

Journal of Nuclear Medicine

Volumn 52, Issue 7, 2011, Pages 1041-1047

  Gains, Jennifer E ^a   Bomanji, Jamshed B ^a   Fersht, Naomi L ^a   Sullivan, Tracy ^a   D'Souza, Derek ^a   Sullivan, Kevin P ^a   Aldridge, Matthew ^a   Waddington, Wendy ^a   Gaze, Mark N ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

177Lu DOTATATE; 68Ga DOTATATE; Childhood neuroblastoma; Molecular radiotherapy; Somatostatin receptor imaging; Targeted radionuclide therapy

Indexed keywords

ANTINEOPLASTIC AGENT; OCTREOTATE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68; OCTREOTATE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; TOPOTECAN; UNCLASSIFIED DRUG; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GALLIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUND; SOMATOSTATIN RECEPTOR;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; SCHOOL CHILD; THROMBOCYTOPENIA; TUMOR VOLUME; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MALE; NEUROBLASTOMA; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79960315800     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.085100     Document Type: Article

References (34)

1. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer. 1992;52:538-543.
2. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. European Neuroblastoma Study Group. Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247-256.
3. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27:1007-1013.
4. Haupt R, Garaventa A, Gambini C, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol. 2010;28:2331-2338.
5. O'Dorisio MS, Chen F, O'Dorisio TM, Wray D, Qualman SJ. Characterisation of somatostatin receptors on human neuroblastoma tumours. Cell Growth Differ. 1994;5:1-8. (Pubitemid 24256928)
6. Albers AR, O'Dorisio MS, Balster DA, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept. 2000;88:61-73. (Pubitemid 30114387)
7. Georgantzi K, Tsolakis AV, Stridsberg M, Jakobson A, Christofferson R, Janson ET. Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma. Pediatr Blood Cancer. November 30, 2010 [Epub ahead of print].
8. Waldherr C, Pless M, Maecke HR, et al. Tumour response and clinical benefit in neuroendocrine tumours after 7.4GBq 90Y-DOTATOC. J Nucl Med. 2002;43:610-616. (Pubitemid 34507110)
9. 90Y-DOTA0Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumours. Semin Nucl Med. 2006;36:147-156.
10. 177Lu-DOTA0,Tyr3]Octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
11. Hofmann M, Maecke H, Börner R, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757. (Pubitemid 33815052)
12. 68Ga]-DOTA-DPhe (1)-Tyr (3) Octreotide in comparison with [111In]-DTPAOC SPECT: first results in patient with neuroendocrine tumours. Mol Imaging Biol. 2003;5:42-48.
13. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617-1626.
14. Gabriel M, Decristoforo C, Kendler D, et al. 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508-518. (Pubitemid 47571404)
15. Haug AR, Auernhammer CJ, Wängler B, et al. 68 Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumours. J Nucl Med. 2010;51:1349-1356.
16. 18F-FDG. Cancer. 2008;112:2447-2455.
17. Reubi JC, Schaer JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
18. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427. (Pubitemid 37056239)
19. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
20. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging and Response to Treatment. J Clin Oncol. 1993;11:1466-1477. (Pubitemid 23228250)
21. Institute of Physics in Engineering and Medicine (IPEM). Medical and Dental Guidance Notes: A Good Practice Guide on All Aspects of Ionising Radiation Protection in the Clinical Environment. York, U.K.: IPEM; 2002.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
23. Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32:123-132. (Pubitemid 34311078)
24. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging. 2003;30:207-216.
25. 3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
26. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25:1054-1060. (Pubitemid 46596756)
27. Taggart D, Dubois S, Matthay KK. Radiolabelled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52:403-418.
28. Matthay KK, Quach A, Huberty J, et al. Iodine-131-Metaiodobenzylguanidine double infusion with autologous stem cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J Clin Oncol. 2009;27:1020-1025.
29. 131I-meta-iodobenzylguanidine with topotecan as a radiosensitiser in children with metastatic neuroblastoma. Cancer Biother Radiopharm. 2005;20:195-199.
30. Forrer F, Mueller-Brand J, Maeke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2005;32:511-512.
31. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues: a review. Q J Nucl Med Mol Imaging. 2010;54:37-51.
32. 90Y-DOTATOC therapy in children and young adults with refractory solid tumours that express somatostatin receptors. J Nucl Med. 2010;51:1524-1531.
33. 90Y biodistribution after selective internal radiotherapy(SIRT) of liver metastases. Eur J Nucl Med Mol Imaging. 2010;37:407-408.
34. 90Y PET. J Nucl Med. 2010;51:1969-1973.